A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms TRAVELL
- 02 Mar 2016 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020, according to ClinicalTrials.gov record.
- 02 Mar 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018, according to ClinicalTrials.gov record.
- 07 Oct 2014 New trial record